Data from Kiadis Pharma’s ongo­ing Phase II tri­al with ATIR101™ will be pre­sent­ed at the American Society of Hematology 2015 Annual Meeting

Amsterdam, The Netherlands, November 3, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive T-cell immunother­a­py treat­ments for blood can­cers and inher­it­ed blood dis­or­ders, today announces that data from the Company’s ongo­ing Phase II clin­i­cal tri­al (NCT01794299/EudraCT 2012-004461-41) with its lead prod­uct ATIR101™ has been select­ed by the American Society of Hematology (ASH) Program Committee for pre­sen­ta­tion at the 57th Annual Meeting in Orlando, Florida on December 7, 2015.
The abstract pro­vides data on Kiadis Pharma’s inter­na­tion­al mul­ti-cen­ter study, in which a total of 23 leukemia patients, includ­ing patients with acute myeloid leukemia (AML), acute lym­phoblas­tic leukemia (ALL) and myelodys­plas­tic syn­drome (MDS), have been enrolled to be treat­ed with ATIR101™ as part of their trans­plant reg­i­men. In addi­tion, the abstract includes a com­par­i­son to a his­toric con­trol group.
Title: Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen
Date: Monday, December 7, 2015 from 6:00 to 8:00 PM EST
Number: 4391
Session: 732. Clinical Allogeneic Transplantation: Results: Poster III
Location: Orange County Convention Center, Hall A

The abstract is sched­uled to be avail­able at on Thursday, November 5, 2015 at 9:00 AM Eastern Standard Time (EST). In addi­tion, the abstract will be pub­lished online in the December 3, 2015 sup­ple­men­tal vol­ume of Blood.

About ATIR101™
For patients suf­fer­ing from blood can­cers, an allo­gene­ic hematopoi­et­ic stem cell trans­plan­ta­tion (HSCT) is gen­er­al­ly regard­ed as the most effec­tive cura­tive approach. During an HSCT treat­ment, the bone mar­row, har­bour­ing the dis­eased can­cer cells, is com­plete­ly destroyed and sub­se­quent­ly replaced by stem cells in the graft from a healthy donor. After an HSCT treat­ment it usu­al­ly takes the patient at least six to twelve months to recov­er to near-nor­mal blood cell lev­els and immune cell func­tions. During this peri­od, the patient is high­ly vul­ner­a­ble to infec­tions caused by bac­te­ria, virus­es and fun­gi but also to dis­ease relapse.
ATIR101™ (Allodepleted T-cell ImmunotheRapeutics) pro­vides for a safe donor lym­pho­cyte infu­sion (DLI) from a par­tial­ly matched (hap­loiden­ti­cal) fam­i­ly mem­ber with­out the risk of caus­ing severe Graft-ver­sus-Host-Disease (GVHD). The T-cells in ATIR101™ will help fight infec­tions and remain­ing tumour cells and there­by bridge the time until the immune sys­tem has ful­ly re-grown from stem cells in the trans­plant­ed graft.
In ATIR101™, T-cells that would cause GVHD are elim­i­nat­ed from the donor lym­pho­cytes using Kiadis Pharma’s pho­tode­ple­tion tech­nol­o­gy, min­imis­ing the risk of GVHD and elim­i­nat­ing the need for pro­phy­lac­tic immune-sup­pres­sion. At the same time, ATIR101™ con­tains poten­tial can­cer killing T-cells from the donor that could elim­i­nate resid­ual can­cer cells and help pre­vent relapse of the dis­ease, known as the Graft-ver­sus-Leukaemia (GVL) effect.
Therefore, ATIR101™, admin­is­tered as an adjunc­tive immuno-ther­a­peu­tic on top of HSCT, pro­vides the patient with func­tion­al, mature immune cells from a par­tial­ly matched fam­i­ly donor that can fight infec­tions and tumour cells but that do not cause GVHD. ATIR101™ thus has the poten­tial to make cura­tive HSCT a viable option to many more patients.
The Company esti­mates that approx­i­mate­ly 35% of patients who are eli­gi­ble and in urgent need of HSCT will not find a match­ing donor in time. A par­tial­ly matched (hap­loiden­ti­cal) fam­i­ly donor, how­ev­er, will be avail­able to over 95% of patients.
ATIR101™, con­sist­ing of donor T-cells that fight infec­tions and resid­ual tumour cells while not elic­it­ing severe GVHD, is designed to result in low relapse rates and low rates of death due to infec­tions, in the absence of severe acute GVHD.

Leave a Reply

Your email address will not be published. Required fields are marked *